Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Background
Bacterial vaginosis is a disorder brought on by an overabundance of the natural flora in the vagina. The most typical clinical sign of this is an increase in fishy-smelling vaginal secretions. Typically, the discharge is thin and can be either white or grey in color.
Women who have been confirmed with vaginosis are more likely to contract other STIs, & expectant women are more likely to give birth before their due date.
Epidemiology
The majority of genital infections in females of reproductive age, known as bacterial vaginosis, are thought to affect 5 to 70 percent of females. It’s interesting to note that, globally, this illness is shown to be least common in Europe and Asia and most common in several regions of Africa.
Around 30 percent of women in the USA between the ages of 14 and 49 are afflicted; however, rates vary among ethnic groups and are particularly prevalent among non-white women (32 percent Mexican Americans, 51 percent African Americans).
According to epidemiological research, women who have had several sex partners, are alone, started having sex at a young age, work as female sex workers, and regularly touch are more likely to report having bacterial vaginosis.
Anatomy
Pathophysiology
The disequilibrium of the naturally existing microbial composition that results in bacterial vaginosis is defined by changes in both the predominant kind of bacteria involved and an increase in the overall number of bacteria involved. The typical vaginal microbiome is dominated by Lactobacilli genera. A decrease in Lactobacilli, in general, is linked to bacterial vaginosis.
Gardnerella vaginalis is assumed to be the primary cause of the majority of bacterial vaginosis infestations; however, the exact cause is still unknown. Gardnerella vaginalis forms a biofilm that enables other opportunistic microbes to proliferate inside the vagina. The connection between BV and a higher risk of developing STIs is based on the fact that BV creates a window of opportunity for other genital bacteria to enter the upper reproductive tract.
In addition, BV causes an increase in the release of endotoxins that promote cytokine & prostaglandin synthesis in the vagina, as well as the accumulation of enzymes that hinder the ability of donor leukocytes to combat infection.
Etiology
The function of transmissibility in bacterial vaginosis is still not well understood, despite the fact that it is not regarded as an infection transmitted sexually. Bacterial vaginosis appears to be caused by an imbalance in the normal microbe flora of the vagina brought on by the transmission of bacteria between people during sexual activity.
This illness is typically brought on by an excess of anaerobes and maybe a decrease in the usual Lactobacilli that normally produce hydrogen peroxide. Gardnerella vaginalis can spread between sex partners when mucosa comes into close contact or when shared sex devices are used.
Gardnerella vaginitis was the name given to bacterial vaginosis in the past because it was thought that these bacteria were to blame for the illness. The term “bacterial vaginosis,” which is more recent, emphasizes the possibility that a variety of alternative bacteria that naturally exist in the vagina may proliferate excessively and result in illness.
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Â
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-non-pharmacological-approach-for-bacterial-vaginosis
Â
Use of antibiotics
The primary pharmaceutical agents used for the treatment of bacterial vaginosis (BV) are antibiotics. These drugs aim to eliminate the overgrowth of harmful bacteria in the vagina and restore a healthy balance to the vaginal microbiome. Â
Metronidazole is a nitroimidazole antibiotic that disrupts the DNA structure of bacteria, leading to their death. Â
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, leading to bacterial death. Â
Tinidazole is a nitroimidazole antibiotic like metronidazole, disrupting bacterial DNA and causing bacterial death.Â
Secnidazole acts by damaging the DNA of bacteria, leading to their destruction.Â
Â
use-of-intervention-with-a-procedure-in-treating-bacterial-vaginosis
Â
use-of-phases-in-managing-bacterial-vaginosis
Â
Medication
300
mg
orally
twice a day
7
days
1
packet
Orally 
daily
2g/day orally for two days or 1g orally every day for five days
500 mg per oral two times daily for seven days
if taking a single dose, 2 gm oral should be the dose per day
500 mg per oral two times daily for seven days
if taking a single dose, 2 gm oral should be the dose per day
Insert 1 tablet into the vagina daily at night before bedtime for 6 days
Pause the treatment during menstruation and continue afterward
Take one tablet once a day
Take one tablet once a day
Clindesse Vaginal Cream: in patients who are not pregnant, one full applicator is placed intravaginally in a single dosage
Cleocin Vaginal Cream: For non-pregnant patients, one full applicator should be placed intravaginally every three or seven days at bedtime, and for pregnant patients, for one week
Cleocin Vaginal Ovules: one suppository is inserted into the vagina for every three consecutive days at bedtime
Xaciato: One full applicator used intravaginally in a single dosage (100 mg of clindamycin every 5 g of gel)
Recommended for the management of bacterial vaginosis (formerly known as anaerobic vaginosis, Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or Corynebacterium vaginitis)
It is advised to administer one applicator's worth of this 0.75% gel—roughly 5 grams, or 37.5 mg of active medication—intravaginally once or twice a day for five days
It is recommended to take this 1.3% gel before bedtime for a once-daily dosage
Dose Adjustments
N/A
Age: >12 years:
1
packet
Orally 
daily
Below 12 years: Safety & efficacy were not established
Above 12 years
Clindesse Vaginal Cream: in patients who are not pregnant, one full applicator is placed intravaginally in a single dosage
Cleocin Vaginal Ovules: one suppository is inserted into the vagina for every three consecutive days at bedtime
Xaciato: One full applicator used intravaginally in a single dosage (100 mg of clindamycin every 5 g of gel)
Safety and efficacy are not seen in pediatrics who are less than 12 years
Recommended for the management of bacterial vaginosis (formerly known as anaerobic vaginosis, Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or Corynebacterium vaginitis)
For children over 12, it is recommended to administer one applicator's worth of this 0.75% gel—roughly 5 grams, or 37.5 mg of active medication—intravaginally once or twice a day for five days
For a once-daily dosage, it is recommended to take this 1.3% gel before bedtime
Future Trends
Bacterial vaginosis is a disorder brought on by an overabundance of the natural flora in the vagina. The most typical clinical sign of this is an increase in fishy-smelling vaginal secretions. Typically, the discharge is thin and can be either white or grey in color.
Women who have been confirmed with vaginosis are more likely to contract other STIs, & expectant women are more likely to give birth before their due date.
The majority of genital infections in females of reproductive age, known as bacterial vaginosis, are thought to affect 5 to 70 percent of females. It’s interesting to note that, globally, this illness is shown to be least common in Europe and Asia and most common in several regions of Africa.
Around 30 percent of women in the USA between the ages of 14 and 49 are afflicted; however, rates vary among ethnic groups and are particularly prevalent among non-white women (32 percent Mexican Americans, 51 percent African Americans).
According to epidemiological research, women who have had several sex partners, are alone, started having sex at a young age, work as female sex workers, and regularly touch are more likely to report having bacterial vaginosis.
The disequilibrium of the naturally existing microbial composition that results in bacterial vaginosis is defined by changes in both the predominant kind of bacteria involved and an increase in the overall number of bacteria involved. The typical vaginal microbiome is dominated by Lactobacilli genera. A decrease in Lactobacilli, in general, is linked to bacterial vaginosis.
Gardnerella vaginalis is assumed to be the primary cause of the majority of bacterial vaginosis infestations; however, the exact cause is still unknown. Gardnerella vaginalis forms a biofilm that enables other opportunistic microbes to proliferate inside the vagina. The connection between BV and a higher risk of developing STIs is based on the fact that BV creates a window of opportunity for other genital bacteria to enter the upper reproductive tract.
In addition, BV causes an increase in the release of endotoxins that promote cytokine & prostaglandin synthesis in the vagina, as well as the accumulation of enzymes that hinder the ability of donor leukocytes to combat infection.
The function of transmissibility in bacterial vaginosis is still not well understood, despite the fact that it is not regarded as an infection transmitted sexually. Bacterial vaginosis appears to be caused by an imbalance in the normal microbe flora of the vagina brought on by the transmission of bacteria between people during sexual activity.
This illness is typically brought on by an excess of anaerobes and maybe a decrease in the usual Lactobacilli that normally produce hydrogen peroxide. Gardnerella vaginalis can spread between sex partners when mucosa comes into close contact or when shared sex devices are used.
Gardnerella vaginitis was the name given to bacterial vaginosis in the past because it was thought that these bacteria were to blame for the illness. The term “bacterial vaginosis,” which is more recent, emphasizes the possibility that a variety of alternative bacteria that naturally exist in the vagina may proliferate excessively and result in illness.
Â
Â
The primary pharmaceutical agents used for the treatment of bacterial vaginosis (BV) are antibiotics. These drugs aim to eliminate the overgrowth of harmful bacteria in the vagina and restore a healthy balance to the vaginal microbiome. Â
Metronidazole is a nitroimidazole antibiotic that disrupts the DNA structure of bacteria, leading to their death. Â
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, leading to bacterial death. Â
Tinidazole is a nitroimidazole antibiotic like metronidazole, disrupting bacterial DNA and causing bacterial death.Â
Secnidazole acts by damaging the DNA of bacteria, leading to their destruction.Â
Â
Â
Â
Bacterial vaginosis is a disorder brought on by an overabundance of the natural flora in the vagina. The most typical clinical sign of this is an increase in fishy-smelling vaginal secretions. Typically, the discharge is thin and can be either white or grey in color.
Women who have been confirmed with vaginosis are more likely to contract other STIs, & expectant women are more likely to give birth before their due date.
The majority of genital infections in females of reproductive age, known as bacterial vaginosis, are thought to affect 5 to 70 percent of females. It’s interesting to note that, globally, this illness is shown to be least common in Europe and Asia and most common in several regions of Africa.
Around 30 percent of women in the USA between the ages of 14 and 49 are afflicted; however, rates vary among ethnic groups and are particularly prevalent among non-white women (32 percent Mexican Americans, 51 percent African Americans).
According to epidemiological research, women who have had several sex partners, are alone, started having sex at a young age, work as female sex workers, and regularly touch are more likely to report having bacterial vaginosis.
The disequilibrium of the naturally existing microbial composition that results in bacterial vaginosis is defined by changes in both the predominant kind of bacteria involved and an increase in the overall number of bacteria involved. The typical vaginal microbiome is dominated by Lactobacilli genera. A decrease in Lactobacilli, in general, is linked to bacterial vaginosis.
Gardnerella vaginalis is assumed to be the primary cause of the majority of bacterial vaginosis infestations; however, the exact cause is still unknown. Gardnerella vaginalis forms a biofilm that enables other opportunistic microbes to proliferate inside the vagina. The connection between BV and a higher risk of developing STIs is based on the fact that BV creates a window of opportunity for other genital bacteria to enter the upper reproductive tract.
In addition, BV causes an increase in the release of endotoxins that promote cytokine & prostaglandin synthesis in the vagina, as well as the accumulation of enzymes that hinder the ability of donor leukocytes to combat infection.
The function of transmissibility in bacterial vaginosis is still not well understood, despite the fact that it is not regarded as an infection transmitted sexually. Bacterial vaginosis appears to be caused by an imbalance in the normal microbe flora of the vagina brought on by the transmission of bacteria between people during sexual activity.
This illness is typically brought on by an excess of anaerobes and maybe a decrease in the usual Lactobacilli that normally produce hydrogen peroxide. Gardnerella vaginalis can spread between sex partners when mucosa comes into close contact or when shared sex devices are used.
Gardnerella vaginitis was the name given to bacterial vaginosis in the past because it was thought that these bacteria were to blame for the illness. The term “bacterial vaginosis,” which is more recent, emphasizes the possibility that a variety of alternative bacteria that naturally exist in the vagina may proliferate excessively and result in illness.
Â
Â
The primary pharmaceutical agents used for the treatment of bacterial vaginosis (BV) are antibiotics. These drugs aim to eliminate the overgrowth of harmful bacteria in the vagina and restore a healthy balance to the vaginal microbiome. Â
Metronidazole is a nitroimidazole antibiotic that disrupts the DNA structure of bacteria, leading to their death. Â
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, leading to bacterial death. Â
Tinidazole is a nitroimidazole antibiotic like metronidazole, disrupting bacterial DNA and causing bacterial death.Â
Secnidazole acts by damaging the DNA of bacteria, leading to their destruction.Â
Â
Â
Â

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
